AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7554709
Drug: Mofegiline (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mofegiline (doses up to 48 mg and 24 mg)
Trial: 7554709
Drug: Mofegiline (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mofegiline (48 mg single dose and 24 mg multiple daily dose)
Trial: 2124210
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g pefloxacin, given orally
Trial: 2124210
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g cefotaxime, given intramuscularly
Trial: 6103255
Drug: Heparin (1
RxNorm normalized name: 2,3-o-Desulfated heparin (12000 da)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1 IU kg‐1 h‐1) administered intravenously for 3‐5 days during and after operation.
Trial: 6103255
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no heparin treatment).
Trial: 6103255
Drug: Heparin administration.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration.
Trial: 31099859
Drug: Twice-Daily Radiotherapy
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-Daily Radiotherapy (TDRT)
Trial: 31099859
Drug: Once-Daily Radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-Daily Radiotherapy (ODRT)
Trial: 20234886
Drug: Oxidized surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidized surface implant
Trial: 20234886
Drug: Machined surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machined surface implant
Trial: 15842028
Drug: 8-session Short
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-session Short Psychodynamic Supportive Psychotherapy + pharmacotherapy
Trial: 15842028
Drug: 16-session Short
RxNorm normalized name: short ragweed pollen extracts
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-session Short Psychodynamic Supportive Psychotherapy + pharmacotherapy
Trial: 30003429
Drug: Physician-implemented medication
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician-implemented medication screening tool
Trial: 30003429
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical and pharmaceutical care
Trial: 26242730
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg orally every twenty four hours)
Trial: 24217313
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (5,000 U weekly for 8 weeks)
Trial: 19615313
Drug: Feitai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feitai Capsule
Trial: 12720535
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate therapy in conjunction with anti-rheumatic therapy
Trial: 12720535
Drug: Anti-rheumatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-rheumatic therapy alone (without etidronate)
Trial: 8408474
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + C-peptide
Trial: 3513531
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg guanfacine daily at bedtime for 8 weeks
Trial: 28664389
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (HPLT 970 ± 15 nm, 3.2 W (50%), 35-6000 Hz, 240 s for four consecutive days, once a day)
Trial: 28664389
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (sham treatment)
Trial: 24601174
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors (sitagliptin) in combination with metformin
Trial: 12730857
Drug: Y-27632 (Rho
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-27632 (Rho kinase inhibitor)
Trial: 11265390
Drug: Cochlear function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear function estimation by otoacoustic emission in children treated with cytostatic drugs for leukemia
Trial: 11265390
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group of healthy children who have never suffered from ear diseases and have never used ototoxic drugs
Trial: 1335217
Drug: Buspirone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (45 to 60 mg/day)
Trial: 3882525
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pirenzepine
Trial: 3882525
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pirenzepine
Trial: 24222526
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment (CBT) programme supplemented with culturally sensitive aspects (CsCBT)
Trial: 24222526
Drug: Culturally sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally sensitive exercise therapy (CsET)
Trial: 17293731
Drug: Bupropion 150
RxNorm normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 150 mg twice daily
Trial: 7910322
Drug: Biosynthetic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic growth hormone (GH) at 4 IU per m2 per day
Trial: 7910322
Drug: Biosynthetic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic growth hormone (GH) at 8 IU per m2 per day
Trial: 3349549
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml coffee (Group 1)
Trial: 3349549
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml orange juice (Group 2)
Trial: 24367124
Drug: 12-month collaborative
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month collaborative care program involving antidepressants and psychotherapy
Trial: 14748464
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg iv 30 min prior to cisplatin, followed by 8 mg orally for 24 h)
Trial: 14748464
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg iv 30 min prior to cisplatin, followed by 20 mg orally for 24 h)
Trial: 8873834
Drug: Parenteral sulbactam-ampicillin
RxNorm normalized name: ampicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral sulbactam-ampicillin (1.5 g, q.i.d.)
Trial: 1954180
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with more than 10% positive NSE cells
Trial: 1954180
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with Chromogranin A
Trial: 6831946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phentolamine and albuterol
Trial: 30075513
Drug: Ramosetron 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.6 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Trial: 30075513
Drug: Ramosetron 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 1.2 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Trial: 1360145
Drug: Trimethoprim-sulfamethoxazole 480
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole 480 mg once a day
Trial: 1360145
Drug: Trimethoprim-sulfamethoxazole 960
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole 960 mg once a day
Trial: 22075088
Drug: Standard multi-dose
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multi-dose hepatitis B vaccine schedule (0, 1, and 6 months)
Trial: 22075088
Drug: Accelerated hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hepatitis B vaccine schedule (0, 1, and 2 months)
Trial: 22075088
Drug: Participants injecting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants injecting drugs more than once a day
Trial: 17912568
Drug: DHA +
RxNorm normalized name: PNV-DHA + Docusate Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA + ARA, soy‐based formula supplemented with at least 17 mg DHA/100 kcal and 34 mg ARA/100 kcal
Trial: 15512377
Drug: sultrin (sulphathiazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sultrin (sulphathiazole 3.42%, sulphacetamide 2.86%, sulphabenzamide 3.7%) pessaries: one pessary twice daily for 5 days
Trial: 1662266
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg per day for 3 weeks)
Trial: 27052530
Drug: Dairy diet
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy diet (3 servings/d of dairy: 375 mL 1% milk-fat milk, 175 g 1.5% MF yogurt, and 30 g of 34% MF cheese)
Trial: 25204404
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1,000 mg/day
Trial: 22739534
Drug: L-arginine buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine buffered with citric acid (ARG.CITR)
Trial: 22739534
Drug: L-arginine buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine buffered with HCl (ARG.HCl)
Trial: 21057255
Drug: Family-based pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based pediatric obesity program (treatment group)
Trial: 2732141
Drug: FCE 22101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 22101 (500 mg, 1000 mg, 750 mg, 1500 mg, 2000 mg)
Trial: 2732141
Drug: FCE 22101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 22101 (1000 mg) with probenecid
Trial: 2732141
Drug: FCE 22101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 22101 (1000 mg) without probenecid
Trial: 2732141
Drug: FCE 22101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 22101 (1000 mg) via im injection
Trial: 2732141
Drug: FCE 22101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE 22101 (continuous infusion at 280 mg/h)
Trial: 30241001
Drug: Buparlisib plus
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib plus fulvestrant (100 mg/day buparlisib continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Trial: 30241001
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus fulvestrant (placebo continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Trial: 26149444
Drug: Stepped-care intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care intervention package for depression, delivered by trained primary health care workers, including psychological interventions and medication based on severity and response.
Trial: 17241576
Drug: Efalizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (1 mg/kg for 12 weeks)
Trial: 17241576
Drug: Efalizumab (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (36 months continuous treatment)
Trial: 10953853
Drug: Intensive control
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive control with metformin
Trial: 8866384
Drug: Ampicillin/sulbactam (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (2.0 g ampicillin + 1.0 g sulbactam every six hours)
Trial: 8866384
Drug: Clindamycin/gentamicin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin/gentamicin (900 mg clindamycin + 1.5 mg/kg gentamicin every eight hours)
Trial: 1727614
Drug: Prednisone and
RxNorm normalized name: chloroprednisone and antiinfectives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone and short-term oral cyclophosphamide
Trial: 6373007
Drug: Hydrocortisone valerate
RxNorm normalized name: Hydrocortisone Valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone valerate 0.2% ointment
Trial: 30415934
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulants (DOACs) within 3-5 days after ischaemic stroke.
Trial: 30415934
Drug: Later initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later initiation of direct oral anticoagulants (DOACs) after >7 days or >14 days post-stroke.
Trial: 12460222
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about benefits of tests and treatment
Trial: 2646729
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone (IVMP) pulse therapy (1 gm) for group 1 (one or two courses) and repeated pulses for group 2 (four to 21 months)
Trial: 25733500
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 to 20 mg/ml for 5 to 7 days)
Trial: 25733500
Drug: Azithromycin (5-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (5-μg disk)
Trial: 25733500
Drug: Azithromycin MIC
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin MIC of ≤ 16 μg/ml or disk inhibition zone size of ≥ 13 mm
Trial: 23835341
Drug: TNF‐α infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α infusion
Trial: 15193831
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/die)
Trial: 2881825
Drug: Somatostatin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (250 micrograms initially as an intravenous bolus and then 250 micrograms/h via infusion)
Trial: 29514706
Drug: ASCTAug (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCTAug (high-dose melphalan with ixazomib)
Trial: 29514706
Drug: ASCTCon (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCTCon (high-dose melphalan)
Trial: 22377973
Drug: Gastroretentive ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastroretentive ER formulation with immediate release component (IR/ER)
Trial: 22377973
Drug: Gastroretentive ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastroretentive ER formulation without immediate release component (ER)
Trial: 22377973
Drug: Conventional ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ER tablet (C-ER)
Trial: 17585027
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg) capsules daily
Trial: 15253389
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of contact with an active leprosy patient and irregular treatment
Trial: 10955437
Drug: Oestriol pessaries
RxNorm normalized name: Oestriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestriol pessaries 0.5 mg every second day for 24 weeks
Trial: 3973310
Drug: Food challenges
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food challenges (71 challenges with doses ranging from 5 to 100 gm)
Trial: 3973310
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 placebos administered)
Trial: 3543241
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (FAC: fluorouracil, doxorubicin, cyclophosphamide) in a protected environment with prophylactic antibiotics
Trial: 3543241
Drug: Standard hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hospital room treatment
Trial: 16502116
Drug: antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antithyroid drug only
Trial: 3541963
Drug: Mesotrin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesotrin (2.5 mg/kg)
Trial: 31914685
Drug: 12-week exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week exercise training (aerobic exercise or combination of aerobic exercise and resistance training)
Trial: 27977757
Drug: DHA plus
RxNorm normalized name: PNV-DHA Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA plus vitamin D (500 mg DHA and 800 IU vitamin D daily)
Trial: 23002493
Drug: Patients administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients administered a selective serotonin reuptake inhibitor
Trial: 23002493
Drug: Patients administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients administered two antipsychotic agents
Trial: 23002493
Drug: Patients administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients administered an opiate
Trial: 23002493
Drug: Patients administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients administered a diuretic non-antihypertensive agent
Trial: 15942629
Drug: ILF (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILF (irinotecan plus high-dose 5-fluorouracil and leucovorin)
Trial: 10362612
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of rhGH (10.0 and 20.0 micrograms/kg)
Trial: 7566950
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (nitroglycerin, calcium channel blocker or both)
Trial: 1982983
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BCH 069 by intravenous injection for 6 weeks 3 times weekly
Trial: 1982983
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BCH 069 by subcutaneous injection for 4 weeks 3 times weekly
Trial: 20227123
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation based on PSA-level groupings
Trial: 20227123
Drug: High-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiotherapy
Trial: 17513327
Drug: Benazepril 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 0.2 mg/kg per day (ACE-I)
Trial: 15727682
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (25 g protein and 60 mg isoflavones)
Trial: 7515999
Drug: Urapidil (35‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (35‐50 mg, n = 10)
Trial: 7515999
Drug: Diltiazem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (25 mg, n = 10)
Trial: 2648447
Drug: Viloxazine (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine (an antidepressant)
Trial: 27603398
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pregabalin orally administered 2 hours before surgery
Trial: 27603398
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally administered 2 hours before surgery
Trial: 24687509
Drug: Primaquine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 30 mg (base)
Trial: 24687509
Drug: Chloroquine 600
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine 600 mg (base)
Trial: 22676397
Drug: Preladenant (5-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant (5-200 mg single doses)
Trial: 22676397
Drug: Preladenant (10-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preladenant (10-200 mg once daily for 10 days)
Trial: 16385906
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment A
Trial: 16385906
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment B
Trial: 12585165
Drug: Puerarin 500
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin 500 mg once a day for 3 weeks